Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20891, USA.
Int J Gynecol Cancer. 2009 Dec;19 Suppl 2(Suppl 2):S2-6. doi: 10.1111/IGC.0b013e3181c03929.
To describe the role of proteomic profiling in the diagnosis and treatment of ovarian cancer.
We report a thorough review of the literature, ongoing trials, and our group's experience with proteomic profiling for early detection, recurrence, and treatment of ovarian cancer.
RESULTS/CONCLUSIONS: Ovarian cancer remains the deadliest gynecologic malignancy in the western world and is most often diagnosed at a rarely curable late stage. Novel applications of proteomic techniques, such as mass spectrometry, show promise in the quest for reliable multimodality screening programs for the early detection of ovarian cancer. Proteomic analysis of tissue samples has underscored the heterogeneity of this disease process. Development of validated assays that survey the genetic and/or proteomic makeup of an individual tumor will add greatly to the histological classification of the tumor and may lead to different treatment approaches tailored to the unique expression pattern of each individual patient. As novel agents that disrupt signal propagation develop, proteomic profiling by reverse-phase protein arrays can characterize the in-tumor efficacy of the agent by quantification of the changes in expression levels of activated proteins. Together, better understanding of the potential diagnostic and therapeutic targets followed with proof-of-target effect will lead to rational combinations of novel therapy and improve individual ovarian cancer patient outcome.
描述蛋白质组学分析在卵巢癌诊断和治疗中的作用。
我们全面回顾了文献、正在进行的试验以及我们小组在蛋白质组学分析方面的早期检测、复发和治疗卵巢癌的经验。
结果/结论：卵巢癌仍然是西方世界最致命的妇科恶性肿瘤，大多数情况下在几乎无法治愈的晚期诊断。蛋白质组技术的新应用，如质谱法，在寻求可靠的多模态筛查方案以早期发现卵巢癌方面显示出希望。对组织样本的蛋白质组分析强调了这种疾病过程的异质性。开发验证性检测方法，调查个体肿瘤的遗传和/或蛋白质组组成，将极大地增加对肿瘤的组织学分类，并可能导致针对每个个体患者独特表达模式的不同治疗方法。随着新型能够阻断信号传递的药物的出现，通过反相蛋白阵列进行蛋白质组分析可以通过定量测定激活蛋白表达水平的变化来描述药物在肿瘤内的疗效。总之，对潜在的诊断和治疗靶点的更好理解，以及对靶标的验证效应，将导致新型疗法的合理联合，并改善卵巢癌患者的个体预后。
